Announcements Trials
Browse Landscape

Phase

Phase 2/3 3Phase 2 1

Status

Recruiting 4Completed 2

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Other hematologic neoplasm 3Lymphoid 3

Conditions

Neoplasms, Plasma Cell 3Neoplasms 3Lymphoma 3Leukemia 3Infections 3Paraneoplastic Syndromes 1

Interventions

Specimen Handling 336Magnetic Resonance Spectroscopy 333Radiotherapy 315Cyclophosphamide 295pembrolizumab 282Cisplatin 266Carboplatin 245Drug Therapy 237Blood Specimen Collection 233Biopsy 206Bevacizumab 187Gemcitabine 177venetoclax 172Radiosurgery 169Capecitabine 165Oxaliplatin 163fludarabine 160Nivolumab 156Paclitaxel 155Standard of Care 137Surveys and Questionnaires 131Surgical Procedures, Operative 130Dexamethasone 127Fluorouracil 125Docetaxel 113tislelizumab 110Rituximab 110Cytarabine 104atezolizumab 101Azacitidine 101

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × OTHER × gamma-Globulins × Clear all
NCT07202065 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)

Monash University

Phase 2/3 Recruiting
900 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07202078 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig)

Monash University

Phase 2/3 Recruiting
900 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT07202091 2025-10-07

Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)

Monash University

Phase 2/3 Recruiting
900 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Infections, Leukemia, Lymphoma, Neoplasms, Neoplasms, Plasma Cell

NCT06373211 2025-02-17

NESPA

Assistance Publique - Hôpitaux de Paris

Phase 2 Recruiting
21 enrolled

Paraneoplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡